Maze Therapeutics (MAZE) News Today $13.49 +0.26 (+1.97%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MAZE Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Q3 EPS Forecast for Maze Therapeutics Lowered by AnalystAugust 19 at 2:56 AM | marketbeat.comLeerink Partnrs Expects Lower Earnings for Maze TherapeuticsAugust 19 at 2:45 AM | americanbankingnews.comResearch Analysts Issue Forecasts for MAZE FY2025 EarningsAugust 17, 2025 | marketbeat.comQ3 EPS Forecast for Maze Therapeutics Increased by AnalystAugust 17, 2025 | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) Stock Rating Upgraded by Wall Street ZenAugust 17, 2025 | americanbankingnews.comMaze Therapeutics (NASDAQ:MAZE) Rating Increased to Hold at Wall Street ZenAugust 17, 2025 | marketbeat.comHC Wainwright Lifts Earnings Estimates for Maze TherapeuticsAugust 17, 2025 | americanbankingnews.comMaze Therapeutics (NASDAQ:MAZE) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPSAugust 14, 2025 | marketbeat.comMaze Therapeutics, Inc.: Buy Rating Backed by Promising Clinical Developments and Strategic TrialsAugust 13, 2025 | tipranks.comResearch Identifies New Ways To Supercharge Cancer ImmunotherapyAugust 13, 2025 | msn.comMaze Therapeutics reports Q2 EPS (77c), consensus ($1.15)August 13, 2025 | msn.comMaze Therapeutics Reports Second Quarter 2025 Financial Results and Recent HighlightsAugust 12, 2025 | globenewswire.comTrv Gp V LLC Acquires Shares of 950,800 Maze Therapeutics, Inc. (NASDAQ:MAZE)August 8, 2025 | marketbeat.comTrv Gp Iv LLC Takes $66.87 Million Position in Maze Therapeutics, Inc. (NASDAQ:MAZE)August 8, 2025 | marketbeat.comHarvard Management Co. Inc. Makes New Investment in Maze Therapeutics, Inc. (NASDAQ:MAZE)August 7, 2025 | marketbeat.comBank of New York Mellon Corp Makes New Investment in Maze Therapeutics, Inc. (NASDAQ:MAZE)August 6, 2025 | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) Shares Down 5.9% - Here's What HappenedAugust 5, 2025 | marketbeat.comMaze Therapeutics, Inc. (NASDAQ:MAZE) Receives Average Recommendation of "Buy" from AnalystsAugust 3, 2025 | marketbeat.comBrokers Set Expectations for MAZE Q2 EarningsJuly 25, 2025 | marketbeat.comHC Wainwright & Co. Initiates Coverage of Maze Therapeutics (MAZE) with Buy RecommendationJuly 24, 2025 | msn.comMaze Therapeutics (NASDAQ:MAZE) Sets New 12-Month High - Time to Buy?July 24, 2025 | marketbeat.comHC Wainwright Begins Coverage on Maze Therapeutics (NASDAQ:MAZE)July 23, 2025 | marketbeat.comMaze Therapeutics, Inc.: Buy Rating Initiated on Precision Nephrology Potential and Undervalued StockJuly 23, 2025 | tipranks.comMaze Therapeutics, Inc.'s (NASDAQ:MAZE) Lock-Up Period To Expire on July 30thJuly 23, 2025 | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) Stock Price Down 5.8% - Time to Sell?July 21, 2025 | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) Sets New 1-Year High - Here's WhyJuly 18, 2025 | marketbeat.comAlphabet Inc. Invests $26.56 Million in Maze Therapeutics, Inc. (NASDAQ:MAZE)July 14, 2025 | marketbeat.comMaze Therapeutics to Participate in Two Upcoming Investor ConferencesJuly 10, 2025 | globenewswire.comQ2 Earnings Forecast for Maze Therapeutics Issued By WedbushJuly 10, 2025 | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) Trading Down 6.6% - Here's What HappenedJuly 9, 2025 | marketbeat.comMAZE Stock Price Quote | MorningstarJuly 9, 2025 | morningstar.comMWedbush Initiates Coverage of Maze Therapeutics (MAZE) with Outperform RecommendationJuly 9, 2025 | msn.comMaze Therapeutics (NASDAQ:MAZE) Shares Gap Up - Here's What HappenedJuly 8, 2025 | marketbeat.comMaze Therapeutics, Inc. (NASDAQ:MAZE) Receives Average Rating of "Buy" from AnalystsJuly 8, 2025 | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) Now Covered by Analysts at WedbushJuly 8, 2025 | marketbeat.comBessemer Group Inc. Makes New $5.31 Million Investment in Maze Therapeutics, Inc. (NASDAQ:MAZE)June 28, 2025 | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) Shares Down 4% - Here's WhyJune 18, 2025 | marketbeat.comGeneral Catalyst Group Management LLC Takes Position in Maze Therapeutics, Inc. (NASDAQ:MAZE)June 13, 2025 | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) Trading 4.7% Higher - Here's WhyJune 12, 2025 | marketbeat.comOdyssey bails on public listing as US IPO landscape stuttersJune 10, 2025 | finance.yahoo.comMaze Therapeutics (NASDAQ:MAZE) Stock Price Down 5.5% - Time to Sell?June 5, 2025 | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) Trading Up 15.6% - Still a Buy?June 3, 2025 | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) Stock Price Up 12.5% - What's Next?May 29, 2025 | marketbeat.comMaze Therapeutics to Participate in the Jefferies 2025 Global Healthcare ConferenceMay 29, 2025 | globenewswire.comMaze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming MilestonesMay 14, 2025 | globenewswire.comMaze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor ConferenceMay 13, 2025 | globenewswire.comMaze Therapeutics (NASDAQ:MAZE) Stock Price Up 11.3% - Here's WhyMay 5, 2025 | marketbeat.comMaze Therapeutics (NASDAQ:MAZE) Shares Down 19.4% - Here's What HappenedApril 27, 2025 | marketbeat.comLeerink Partnrs Analysts Lower Earnings Estimates for MAZEApril 5, 2025 | marketbeat.comMaze Therapeutics' (MAZE) Buy Rating Reaffirmed at GuggenheimApril 4, 2025 | marketbeat.com Get Maze Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MAZE and its competitors with MarketBeat's FREE daily newsletter. Email Address MAZE Media Mentions By Week MAZE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MAZE News Sentiment▼0.450.66▲Average Medical News Sentiment MAZE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MAZE Articles This Week▼142▲MAZE Articles Average Week Get Maze Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MAZE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Recursion Pharmaceuticals News Today Tarsus Pharmaceuticals News Today Ocular Therapeutix News Today Belite Bio News Today IDEAYA Biosciences News Today Agios Pharmaceuticals News Today Denali Therapeutics News Today Disc Medicine News Today Harmony Biosciences News Today Galapagos News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MAZE) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maze Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maze Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access